These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis. Mohamed BA; Barakat AZ; Zimmermann WH; Bittner RE; Mühlfeld C; Hünlich M; Engel W; Maier LS; Adham IM J Mol Cell Cardiol; 2012 Oct; 53(4):459-68. PubMed ID: 22884543 [TBL] [Abstract][Full Text] [Related]
43. Mechanisms of physiological and pathological cardiac hypertrophy. Nakamura M; Sadoshima J Nat Rev Cardiol; 2018 Jul; 15(7):387-407. PubMed ID: 29674714 [TBL] [Abstract][Full Text] [Related]
44. Adrenergic Receptor Regulation of Mitochondrial Function in Cardiomyocytes. Sandroni PB; Fisher-Wellman KH; Jensen BC J Cardiovasc Pharmacol; 2022 Sep; 80(3):364-377. PubMed ID: 35170492 [TBL] [Abstract][Full Text] [Related]
45. The biochemical response of the heart to hypertension and exercise. Wakatsuki T; Schlessinger J; Elson EL Trends Biochem Sci; 2004 Nov; 29(11):609-17. PubMed ID: 15501680 [TBL] [Abstract][Full Text] [Related]
48. microRNA-133a attenuates cardiomyocyte hypertrophy by targeting PKCδ and Gq. Lee SY; Lee CY; Ham O; Moon JY; Lee J; Seo HH; Shin S; Kim SW; Lee S; Lim S; Hwang KC Mol Cell Biochem; 2018 Feb; 439(1-2):105-115. PubMed ID: 28795305 [TBL] [Abstract][Full Text] [Related]
49. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Tham YK; Bernardo BC; Ooi JY; Weeks KL; McMullen JR Arch Toxicol; 2015 Sep; 89(9):1401-38. PubMed ID: 25708889 [TBL] [Abstract][Full Text] [Related]
50. Cardiac function in genetically engineered mice with altered adrenergic receptor signaling. Rockman HA; Koch WJ; Lefkowitz RJ Am J Physiol; 1997 Apr; 272(4 Pt 2):H1553-9. PubMed ID: 9139936 [TBL] [Abstract][Full Text] [Related]
51. Noncoding RNAs in Cardiac Hypertrophy. Li Y; Liang Y; Zhu Y; Zhang Y; Bei Y J Cardiovasc Transl Res; 2018 Dec; 11(6):439-449. PubMed ID: 30171598 [TBL] [Abstract][Full Text] [Related]
52. Cardiac and Vascular α Kaykı-Mutlu G; Papazisi O; Palmen M; Danser AHJ; Michel MC; Arioglu-Inan E Cells; 2020 Nov; 9(11):. PubMed ID: 33158106 [TBL] [Abstract][Full Text] [Related]
53. Alpha-1-adrenergic receptors in heart failure: the adaptive arm of the cardiac response to chronic catecholamine stimulation. Jensen BC; OʼConnell TD; Simpson PC J Cardiovasc Pharmacol; 2014 Apr; 63(4):291-301. PubMed ID: 24145181 [TBL] [Abstract][Full Text] [Related]
54. Src tyrosine kinase promotes cardiac remodeling induced by chronic sympathetic activation. Li W; Zhu Y; Wang W; He D; Feng L; Li Z Biosci Rep; 2023 Oct; 43(10):. PubMed ID: 37650260 [TBL] [Abstract][Full Text] [Related]
56. mAKAP-a master scaffold for cardiac remodeling. Passariello CL; Li J; Dodge-Kafka K; Kapiloff MS J Cardiovasc Pharmacol; 2015 Mar; 65(3):218-25. PubMed ID: 25551320 [TBL] [Abstract][Full Text] [Related]
57. Reversal of cardiac remodeling by modulation of adrenergic receptors: a new frontier in heart failure. Perrino C; Rockman HA Curr Opin Cardiol; 2007 Sep; 22(5):443-9. PubMed ID: 17762546 [TBL] [Abstract][Full Text] [Related]
58. S100beta inhibits alpha1-adrenergic induction of the hypertrophic phenotype in cardiac myocytes. Tsoporis JN; Marks A; Kahn HJ; Butany JW; Liu PP; O'Hanlon D; Parker TG J Biol Chem; 1997 Dec; 272(50):31915-21. PubMed ID: 9395540 [TBL] [Abstract][Full Text] [Related]